Loading...

PSNL PERSONALIS INC Company Mergers 8-K Filing

PRSN

PSNL

PERSONALIS INC

(PSNL)

2025 8-K

Management Change

Financial Results Update

Financial Results Update

Stock Offering Announcement

Medicare Rate Update

Medicare Coverage Approval

Financial Results Update

New VA Contract

Financial Statements

Financial Statements

Financial Results

Preliminary Results

Sales Agreement Update

Investment Agreement

Financial Results

New Contract Award

Investment Agreement

Earnings Reports

Settlement and License Agre...

Annual Meeting of Stockholders

Earnings Reports

Earnings Reports

Earnings Reports

Agreement Extension

Workforce Reduction

Agreement with Tempus Labs,...

Earnings Reports

Management Changes

Dismissal and Engagement of...

Annual Meeting of Stockholders

Earnings Reports

Earnings Reports

Workforce Reduction

Earnings Reports

External Links:

On November 24, 2025, Personalis, Inc. announced that Medicare will adjust reimbursement rates for their cancer recurrence tests starting December 1, 2025: $4,266 for the NeXT Personal Dx Breast MRD test and $1,164 for the NeXT Personal Single Plasma Test.

AI Assistant

PERSONALIS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.